Repligen Corporation (RGEN)
Repligen Corporation (RGEN) is a healthcare company (medical instruments & supplies) based in the United States. The share price is $162.51, down 0.17% on the day, which values the company at $10.39B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $162.51−0.17% today
- Market value
- $10.39B
- Forward P/E
- 61.3×
- Funk Score
- 44/100
- Against its own history
- About its usual priceusual price $158.64
- 200-week average
- $151.967% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Repligen Corporation in more detail
RGEN trades at 61.3× next year's expected earnings, 12.9× sales. Measured against its own history, the price is 2% above what its usual multiples would imply ($158.64) — about its usual price. It sits 7% above its 200-week average of $151.96.
Over the last five fiscal years Repligen Corporation has compounded revenue 15.0% a year, earnings per share -5.0% a year, free cash flow 17.9% a year. Its Funk Score is 44 out of 100 (financial strength 5.6, profitability 3.3, growth 4.9, value 3.7, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Thin interest cover; Low return on invested capital.
6 of the superinvestors tracked here hold RGEN, including Lee Ainslie (2.4% of the portfolio), Wallace Weitz (0.5% of the portfolio), Brandon Haley (0.4% of the portfolio).
Superinvestors holding RGEN
6 of the investors tracked here report a position in their latest 13F filing.
- Lee Ainslie Maverick Capital2.44% of portfolio · $270.8M · added · Q2 2026
- Wallace Weitz Weitz Investment Management0.54% of portfolio · $7.8M · Q3 2026
- Brandon Haley Holocene Advisors0.40% of portfolio · $176.3M · added · Q2 2026
- Chuck Royce (founder) Royce & Associates0.28% of portfolio · $30.2M · trimmed · Q3 2026
- Stanley Druckenmiller Duquesne Family Office0.24% of portfolio · $10.6M · new · Q2 2026
- Ron Baron Baron Capital (BAMCO)0.24% of portfolio · $142.4M · trimmed · Q3 2026
Health Care companies of similar size
- Cooper CompaniesCOO
- Fresenius Medical CareFMS
- Kymera TherapeuticsKYMR
- DaVitaDVA
- Halozyme TherapeuticsHALO
- Universal Health ServicesUHS
- Bio-TechneTECH
- BioMarin PharmaceuticalBMRN
- AvantorAVTR
- Ensign GroupENSG
- VaxcytePCVX
- Bio-Rad LaboratoriesBIO
Side by side:RGEN vs TECH (Repligen Corporation vs Bio-Techne)RGEN vs UHS (Repligen Corporation vs Universal Health Services)RGEN vs HALO (Repligen Corporation vs Halozyme Therapeutics)RGEN vs DVA (Repligen Corporation vs DaVita)RGEN vs KYMR (Repligen Corporation vs Kymera Therapeutics)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Repligen Corporation (RGEN): questions and answers
What is RGEN's PEG ratio?
Repligen Corporation's PEG ratio is 1.62 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Repligen Corporation's market cap?
Repligen Corporation is valued at $10.39B at a share price of $162.51.
Is RGEN overvalued or undervalued?
Against its own history, RGEN is about its usual price: the price is 2% above the $158.64 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is RGEN above its 200-week moving average?
Yes. RGEN is 6.9% above its 200-week average of $151.96. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Repligen Corporation growing?
Over the last five fiscal years Repligen Corporation's revenue grew 15.0% a year and its earnings per share -5.0% a year; over ten years revenue grew 24.3% a year.
Does RGEN pay a dividend?
Repligen Corporation does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Repligen Corporation (RGEN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RGEN
Underlying data: Yahoo Finance; company filings with the SEC.